ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections in vulnerable populations through the development of host defence immune enhancers.
ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defence enhancers to combat respiratory viral infections by boosting the body’s local innate immune response. Its lead product, INNA-051, is a once-a-week nasal dry powder designed to reduce the impact of viral infections and prevent complications in at-risk populations, including the elderly and those with chronic medical conditions.
Being virus-agnostic, INNA-051 offers solutions to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.
Headquartered in Melbourne, Australia, the company has raised US$33 million in financing from Brandon Capital, The Minderoo Foundation and Uniseed. It has partnered with the US COPD Foundation and has been awarded a US$13.1M contract from the U.S. Department of Defense. It is an alumni member of BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate novel potential solutions for future pandemics.
